[Belimumab for the treatment of Systemic Lupus Erythematosus]
Secco A, Augustovski F, Pichon-Riviere A, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001155
Spanish
Authors' recommendations:
There is evidence of high methodological quality, showing that belimumab has a mild/moderate efficacy in the treatment of adult patients with autoantibody-positive systemic lupus erythematosus and high level of disease activity in spite of standard treatment. It is not recommended for those patients with severe central nervous system involvement and/or severe lupus nephritis. The international guidelines recommend it as an alternative in these types of patients and the health sponsors surveyed (U.S.) cover it. However, its use is not recommended by health technology assessments from countries such as the United Kingdom, Scotland or Canada, because of its uncertain effectiveness and cost-effectiveness.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.iecs.org.ar/publicacion/?id=5539
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Argentina
MeSH Terms
- Immunosuppressive Agents
- Lupus Erythematosus, Systemic
- Antibodies, Monoclonal, Humanized
Contact
Organisation Name:
Institute for Clinical Effectiveness and Health Policy
Contact Address:
Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name:
info@iecs.org.ar
Contact Email:
info@iecs.org.ar
Copyright:
Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.